Sep 2026· Current Opinion in HIV and AIDS· Vol 21, pp. 442-449· 0 citations· 33 references
Medicine
TL;DR
Progress is being made in developing vaccine immunogens that induce bnAb B cell lineages in humans and the remaining tasks needed to complete a prototype HIV vaccine are outlined.
Abstract
Purpose
OF REVIEW
Since our last review of progress in inducing HIV broadly neutralizing antibodies (bnAbs) in 2023, advances have been made in achieving bnAb induction in humans. The purpose of this review is to discuss this progress and to outline remaining tasks needed to complete a prototype HIV vaccine.
RECENT
Findings
Several published clinical trials have succeeded in inducing bnAb precursors of multiple types, including membrane proximal external region (MPER), CD4+-mimicking CD4+-binding site (bs) and HCDR3-dominant CD4bs. Trials are underway or nearing completion for inducing V2-apex and V3-glycan bnAb precursors.
SUMMARY
Progress is being made in developing vaccine immunogens that induce bnAb B cell lineages in humans. The next tasks are to design boosting immunogens that complete bnAb affinity maturation, and to do so for two to three different bnAb specificities to prevent transmitted-founder virus escape during HIV transmission. A final task is to utilize a vaccine platform that will induce high-tittered, durable serum bnAb activity capable of providing protection for multiple years.
Abstract Background Immune checkpoint inhibitors improve outcomes in clear cell renal cell carcinoma (ccRCC), yet most patients do not achieve durable responses due in part to insufficient tumor antigenicity. While neoantigen vaccines have shown promising early-phase results in ccRCC, their patient-specific design limi...
F. Scallo, A. Dighe, Josephine Burdekin et al.· The Oncologist· 0 citations
Summary We evaluate the efficacy and immunogenicity of HIV clade A/E A244 envelope (Env) immunogens with the 23 amino acids of variable region 1 deleted (ΔV1) or retained (wild-type [WT]) in macaques. Only the ΔV1 regimen significantly reduces the risk of mucosal acquisition of clade C simian/human immunodeficiency vir...
Isabela Silva de Castro, Mohammad Arif Rahman, Massimiliano Bissa et al.· Cell Reports Medicine· 0 citations
A framework for optimal personalized neoAg vaccination in B-lymphoma is defined and it is demonstrated that neoAg vaccines can safely synergize with CD8+ T cell-selective immunotherapies to prevent T-cell dysfunction and generate durable systemic anti-tumor immunity.
Yuang Song, E. Aladyeva, Ruan F. Vieira Medrano et al.· bioRxiv· 0 citations
The integration of immunotherapy into neoadjuvant treatment for triple-negative breast cancer (TNBC) has improved outcomes in some patients. Pre-clinical investigation of immunotherapy resistance in the aggressive 4T1 TNBC model has been hampered by a lack of known tumour-specific epitopes. Using proteomic and functi...
Pouya Faridi, D. Zanker, Nicole M. Haynes et al.· Cancer Immunology and Immuno...· 0 citations
Human metapneumovirus (HMPV) is a leading cause of acute respiratory tract infections in infants, older adults, and immunocompromised individuals; however, no licensed vaccine is currently available. This study employed an immunoinformatics-guided reverse vaccinology approach to design novel BAFF- and APRIL-adjuvan...
Reham M. Alahmadi, M. Awadalla, Halah Z. AlRawi et al.· Frontiers in Virology· 0 citations
Natural killer group 2 family of receptor A (NKG2A) and its ligand human leukocyte antigen-E (HLA-E) are increasingly recognised as an important immune checkpoint restraining lymphocyte populations involved in cancer immunity. Recent clinical studies investigating dual NKG2A/programmed death ligand 1 (PD-L1) blockade...
Maria C. Melander, Franziska Uhlenbrock, Anne Worsaae et al.· Frontiers in Oncology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
